ADMA Biologics (NASDAQ:ADMA) Stock Price Up 7.6% on Analyst Upgrade

ADMA Biologics Inc (NASDAQ:ADMA)’s stock price traded up 7.6% during trading on Wednesday after Raymond James Financial upgraded the stock to a moderate buy rating. Raymond James Financial now has a $21.00 price target on the stock. ADMA Biologics traded as high as $8.77 and last traded at $8.7350. 314,986 shares were traded during mid-day trading, a decline of 94% from the average session volume of 5,151,083 shares. The stock had previously closed at $8.12.

A number of other brokerages have also recently commented on ADMA. Zacks Research cut shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, May 26th. Cantor Fitzgerald reiterated a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Wall Street Zen cut shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Mizuho decreased their target price on shares of ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Finally, Canaccord Genuity Group decreased their target price on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $19.67.

Insider Activity

In other news, Director Jerrold B. Grossman acquired 12,500 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were purchased at an average price of $8.01 per share, for a total transaction of $100,125.00. Following the completion of the transaction, the director owned 513,884 shares of the company’s stock, valued at $4,116,210.84. The trade was a 2.49% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 3.90% of the company’s stock.

Key Headlines Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Raymond James upgraded ADMA Biologics to “moderate buy” and set a $21 price target, implying significant upside from recent levels. The Fly / Zacks report
• Neutral Sentiment: Multiple law firms, including Rosen Law Firm, Kirby McInerney, Robbins Geller, Faruqi & Faruqi, and others, announced or reminded investors about a class-action lawsuit and the August 10, 2026 lead-plaintiff deadline. This keeps the legal situation in focus but does not add new business fundamentals.
• Negative Sentiment: The class action alleges ADMA Biologics engaged in channel stuffing, used an undisclosed related-party transaction, and lacked adequate internal controls, which could indicate prior revenue quality concerns and create downside risk if claims gain traction. Holzer & Holzer class action alert
• Negative Sentiment: Several articles frame the stock’s recent weakness as tied to the lawsuit news and claim it followed a sharp prior drop, reinforcing concerns that litigation headlines are the main driver of sentiment right now. BFA Law alert

Hedge Funds Weigh In On ADMA Biologics

A number of hedge funds have recently modified their holdings of ADMA. Royal Bank of Canada increased its position in shares of ADMA Biologics by 112.7% in the first quarter. Royal Bank of Canada now owns 95,885 shares of the biotechnology company’s stock valued at $1,903,000 after acquiring an additional 50,801 shares during the period. Ashton Thomas Private Wealth LLC purchased a new position in shares of ADMA Biologics in the first quarter valued at about $217,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of ADMA Biologics by 59.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 816,590 shares of the biotechnology company’s stock valued at $16,201,000 after acquiring an additional 305,064 shares during the period. Norges Bank purchased a new position in shares of ADMA Biologics in the second quarter valued at about $549,000. Finally, EverSource Wealth Advisors LLC increased its position in shares of ADMA Biologics by 385.8% in the second quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 2,180 shares during the period. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Price Performance

The business’s 50-day simple moving average is $9.19 and its 200-day simple moving average is $14.20. The stock has a market cap of $1.93 billion, a PE ratio of 12.24 and a beta of 0.72. The company has a quick ratio of 3.93, a current ratio of 6.95 and a debt-to-equity ratio of 0.51.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.19. The firm had revenue of $114.49 million for the quarter, compared to analyst estimates of $139.98 million. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The company’s revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.11 EPS. On average, research analysts expect that ADMA Biologics Inc will post 0.84 EPS for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.